Zencurix Signs Distribution Agreement with Turkey's Neogen and Jin's Well BCT... "Accelerating Overseas Expansion"

[Asia Economy Reporter Hyunseok Yoo] GenCurix, a liquid biopsy molecular diagnostics specialist company, announced on the 6th that it has signed a local dealership supply contract with Neogen Diagnostik (hereinafter Neogen), a diagnostic device distributor located in Istanbul, Turkey.

Through this contract, GenCurix plans to provide testing services to six countries in Eastern Europe and Central Asia, including Turkey, Azerbaijan, and Ukraine, via Neogen. In particular, many countries including Turkey do not require separate local approval procedures, so immediate sales are expected to occur through this contract.

JinswellBCT is the first and only breast cancer prognosis diagnostic test in Asia to obtain official approval from national institutions. After completing code registration at domestic general hospitals in September and starting sales through direct prescriptions, sales have begun in earnest.

The company’s strategy is to expand its scope from the recently launched breast cancer prognosis diagnostic test ‘JinswellBCT’ and companion diagnostic test ‘Dropplex’ to early diagnosis tests. It is also in the process of obtaining regulatory approval for early diagnosis products for liver cancer and colorectal cancer liquid biopsies, aiming to complete this by the first half of next year.

A GenCurix official stated, “Since the start of domestic sales, inquiries about JinswellBCT, which was the world’s first to conduct clinical trials and receive approval in Asia, have been pouring in from overseas as well,” adding, “We will strive to contribute to performance growth through securing additional overseas dealerships and active marketing.”

This content was produced with the assistance of AI translation services.